A05SQUIRE: a randomised, multicentre, open-label, phase III...

A05SQUIRE: a randomised, multicentre, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC); Subgroup efficacy and safety data for pts with epidermal growth factor receptor (EGFR)-expressing tumours

Zilembo, N., Giannetta, L., Crinò, L., Bearz, A., Amoroso, D., Gamucci, T., Buscaglia, M., Tiseo, M., Soldatenkova, V., Chouaki, N., Depenbrock, H., Hirsch, F.R., Paz-Ares, L., Bidoli, P.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw332.05
Date:
September, 2016
File:
PDF, 76 KB
2016
Conversion to is in progress
Conversion to is failed